Clinical Trial Update: FHD-286 in Subjects With Metastatic Uveal Melanoma [Phase 1]

View source ↗

Summary

The Phase 1 study of FHD-286 in metastatic uveal melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• FHD-286

Snippet

Sponsor: Foghorn Therapeutics Inc. | Conditions: Metastatic Uveal Melanoma | Phase 1 | Status: TERMINATED